Quiver AI Summary Eisai Co., Ltd. and Biogen Inc. have provided an update on the regulatory review of their Alzheimer’s disease treatment, lecanemab, in the European Union.

Pharma Eisai, Biogen's Alzheimer's drug Leqembi wins over FDA experts in unanimous vote By Eric Sagonowsky Jun 9, 2023 3:55pm Biogen Eisai Pharma ...

--Biogen and Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration has extended the review period by three months for the Biologics License Application for aducanumab, an ...

Eisai said Friday that it intends to push ahead with the development of a second Alzheimer’s drug, called BAN2401, also part of the Biogen partnership.

Eisai and Biogen’s September press release described what are known as topline results, indicating that the trial met its main and secondary goals and summarizing reported side effects.

In September, Eisai and Biogen shocked analysts by reporting that a phase 3 clinical trial of lecanemab hit its primary endpoint, ending a long string of failures for anti-amyloid antibodies.

Biogen and Eisai are committed to addressing health equity for underserved and underrepresented populations that are at higher risk for Alzheimer’s disease. Black/African Americans and Latinx people ...

Eisai and Biogen get another chance. Read why the latest from the two companies is a big step forward even though it's still just a glimmer of hope for Alzheimer’s sufferers.

Eisai and Biogen began their Alzheimer’s disease alliance in 2014. Under the agreement the partners will share in the costs of developing and commercializing Alzheimer’s drugs from both companies.

Biogen and Eisai will now co-promote Biogen’s multiple sclerosis (MS) treatments, AVONEX ® (interferon beta 1a), TYSABRI ® (natalizumab), and TECFIDERA ® (dimethyl fumarate) in Japan to ...

In an 857-patient Phase 2 study, Eisai and Biogen reported in 2017 that the drug, then known as BAN2401, did not meet the trial’s main goal at 12 months. But the partners kept the study blinded ...